FDA accepts Amneal’s NDA for IPX203 to treat Parkinson’s disease

FDA accepts Amneal’s NDA for IPX203 to treat Parkinson’s disease

Submitted by admin on November 14, 2022 - 10:31am
Source: 
Pharmaceutical Business Review
News Tags: 
Amneal
FDA
IPX203
Parkinson's Disease
Headline: 
FDA accepts Amneal’s NDA for IPX203 to treat Parkinson’s disease
snippet: 


The US Food and Drug Administration (FDA) has accepted Amneal Pharmaceuticals’ new drug application (NDA) for IPX203 to treat Parkinson’s disease (PD).

Do Not Allow Advertisers to Use My Personal information